文献速递心外重症与机械循环支持

左心室辅助装置撤停用于心肌恢复:长期心室重构与不良事件

LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events.
PubMed 文献 · J Heart Lung Transplant · 2021-08-11

双中心回顾性分析17例经选择行微创LVAD撤停(装置保留体内)的心肌恢复患者,随访至3年。撤停后1个月LVEF由55%降至48%(p=0.03),LVIDd由4.8cm增至5.2cm(p=0.10),6个月后趋于稳定;无心衰住院、LVAD再植入或移植的生存率1年为94%、3年为78%,但41%患者反复感染致3例死亡和1例完全摘除装置。

要点

  • 心肌恢复后微创LVAD撤停(装置保留)3年无事件生存率78%,心功能和心室大小稳定。
  • 撤停后1个月LVEF较撤停前下降(55%→48%,p=0.03),6个月后稳定至3年。
  • 反复感染发生率达41%,是撤停策略的主要不良事件,需重点防治。

核心结论

  • 心肌恢复后行LVAD撤停(装置保留体内)与良好的长期无复发性心衰生存相关,并维持心室大小和功能至3年。
  • 减少反复感染仍是该管理策略的重要治疗目标。

研究设计与样本

  • 双中心回顾性分析,纳入2010年5月至2020年1月间达到应答标准(LVEF≥40%且LVIDd≤6.0cm)并因心肌恢复行择期LVAD撤停的患者。
  • 共17例患者纳入分析,所有患者均行流出道人工血管闭合和驱动线切除,LVAD保留体内;排除因感染或装置血栓行紧急撤停者。
  • 研究期间515例接受LVAD的患者中29例(5.6%)实现心肌恢复,其中12例行完全摘除或紧急撤停被排除。
  • 随访采用系列超声心动图至3年;主要临床结局为无心力衰竭住院、LVAD再植入或移植的生存。

主要发现

  • 患者LVAD植入时中位年龄42岁(IQR 25-54岁),均为非缺血性心肌病,5例(29%)为女性。
  • LVAD植入时中位LVEF为10%(IQR 5%-15%),LVIDd为6.6cm(IQR 5.8-7.1cm);11例(65%)为流体动力悬浮离心泵,6例(35%)为轴流泵。
  • 撤停前LVAD支持中位时间为28.7个月(范围13.5-36.2个月)。
  • 撤停后1个月中位LVEF从55%降至48%(p=0.03),LVIDd从4.8cm增至5.2cm(p=0.10);至6个月逐渐重构,此后至3年随访无统计学差异(LVEF 42%,LVIDd 5.6cm)。
  • 反复感染影响41%患者,导致3例死亡和1例完全摘除装置;1例复发心衰需移植;无心衰、LVAD或移植的生存概率1年为94%,3年为78%。

临床怎么用

  • 对于LVAD支持后达到心肌恢复标准(LVEF≥40%且LVIDd≤6.0cm)的患者,可考虑择期微创撤停并保留装置。
  • 撤停后需密切监测心功能和心室大小,尤其关注早期(1-6个月)的重构变化。
  • 应积极预防和管理感染,以降低撤停后的不良事件风险。

局限性

  • 回顾性双中心设计,样本量小(17例),可能存在选择偏倚。
  • 未设对照组,无法直接比较装置保留与完全摘除或其他策略的差异。
  • 随访至3年,更长期的安全性和恢复可持续性尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular assist devices (LVADs) mechanically unload the heart and coupled with neurohormonal therapy can promote reverse cardiac remodeling and myocardial recovery. Minimally invasive LVAD decommissioning with the device left in place has been reported to be safe over short-term follow-up. Whether device retention reduces long-term safety, or sustainability of recovery is unknown. METHODS: This is a dual-center retrospective analysis of patients who had achieved responder status (left ventricular ejection fraction, LVEF ≥40% and left ventricular internal diastolic diameter, LVIDd ≤6.0 cm) and underwent elective LVAD decommissioning for myocardial recovery from May 2010 to January 2020. All patients had outflow graft closure and driveline resection with the LVAD left in place. Emergent LVAD decommissioning for an infection or device thrombosis was excluded. Patients were followed with serial echocardiography for up to 3-years. The primary clinical outcome was survival free of heart failure hospitalization, LVAD reimplantation, or transplant. RESULTS: During the study period 515 patients received an LVAD and 29 (5.6%) achieved myocardial recovery, 12 patients underwent total device explantation or urgent device decommissioning, 17 patients underwent elective LVAD decommissioning, and were included in the analysis. Median age of patients at LVAD implantation was 42 years (interquartile range, IQR: 25-54 years), all had a nonischemic cardiomyopathy, and 5 (29%) were female. At LVAD implantation, median LVEF was 10% (IQR: 5%-15%), and LVIDd 6.6 cm (IQR: 5.8-7.1 cm). There were 11 hydrodynamically levitated centrifugal-flow (65%), and 6 axial-flow LVADs (35%). The median duration of LVAD support before decommissioning was 28.7 months (range 13.5-36.2 months). As compared to the turndown study parameters, 1-month post-decommissioning, median LVEF decreased from 55% to 48% (p = 0.03), and LVIDd increased from 4.8 cm to 5.2 cm (p = 0.10). There was gradual remodeling until 6 months, after which there was no statistical difference on follow-up through 3-years (LVEF 42%, LVIDd 5.6 cm). Recurrent infections affected 41% of patients leading to 3 deaths and 1 complete device explant. Recurrent HF occurred in 1 patient who required a transplant. Probability of survival free of HF, LVAD, or transplant was 94% at 1-year, and 78% at 3-years. CONCLUSIONS: LVAD decommissioning for myocardial recovery was associated with excellent long-term survival free from recurrent heart failure and preservation of ventricular size and function up to 3-years. Reducing the risk of recurrent infections, remains an important therapeutic goal for this management strategy.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Gerhard EF, Wang L, Singh R, et al. LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events. J Heart Lung Transplant. 2021. PMID: 34479776. doi:10.1016/j.healun.2021.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。